Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-17A-TSB
- Development stage
- Preclinical
- Lead developer
- TargetSite Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intravitreal, Topical
01
Overview
IL-17A-TSB (also known as TSB17) is a preclinical-stage mRNA-targeted oligonucleotide (TargetSite Blocker or TSB) developed by TargetSite Therapeutics, a Yale University spinout. It is designed to selectively destabilize human IL-17A mRNA by blocking the interaction of microRNA-466 (specifically miR-466l-3p) with the 3'-untranslated region (3'-UTR) of IL-17A mRNA. Under normal inflammatory conditions, miR-466 acts non-conventionally to stabilize IL-17A transcripts in coordination with the RNA-binding protein HuR (human antigen R). By preventing miR-466 binding, IL-17A-TSB disrupts this stabilizing cooperation, leading to rapid transcript decay and suppression of IL-17A protein expression. The therapeutic candidate has demonstrated efficacy in preclinical animal models of multiple sclerosis (experimental autoimmune encephalomyelitis, or EAE), psoriasis, and autoimmune uveitis.
- Other names
- IL-17A TargetSite BlockerIL17A TargetSite BlockerIL 17A TargetSite BlockerIL-17A-targeted TSBIL17A-targeted TSBIL 17A-targeted TSBmiR-466-IL-17A TSBmiR466-IL-17A TSBmiR 466-IL-17A TSBmiR466-IL17A Target site blockermiR-466-IL17A Target site blockermiR 466-IL17A Target site blocker
02
Targets
ELAVL1 (Human Antigen R)miR-466l-3p (microRNA-466l-3p)Interleukin-17A mRNA microRNA-binding site in the 3′-untranslated regionIL-17A (Interleukin-17A)
Beyond the preview
Go deeper on IL-17A-TSB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-17A-TSB.